<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Cytoreductive surgery (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e>) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been shown to improve survival in selected patients with <z:e sem="disease" ids="C1332128" disease_type="Neoplastic Process" abbrv="">peritoneal carcinomatosis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We review our institutional experience with the procedure and evaluate the overall survival (OS) and disease-free survival (DFS) rates in 100 consecutive patients </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Data were prospectively collected from 100 consecutive patients with <z:e sem="disease" ids="C1332128" disease_type="Neoplastic Process" abbrv="">peritoneal carcinomatosis</z:e> treated by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> and HIPEC at the National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Centre Singapore between April 2001 and May 2012 </plain></SENT>
<SENT sid="3" pm="."><plain>Our primary end points were OS and DFS </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Of the 100 patients, 84 were of Chinese ethnicity, 3 were Malay, 6 were Indian, and 7 were of other ethnicities </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">Primary tumors</z:e> were <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> (n = 39), <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (n = 28), primary peritoneal (n = 6), <z:e sem="disease" ids="C0496779" disease_type="Neoplastic Process" abbrv="">appendiceal cancer</z:e> (n = 20), and <z:mpath ids='MPATH_365'>mesothelioma</z:mpath> (n = 7) </plain></SENT>
<SENT sid="6" pm="."><plain>Median follow-up duration was 21 months </plain></SENT>
<SENT sid="7" pm="."><plain>At 5 years, the DFS was 26.3 % and OS was 50.9 % </plain></SENT>
<SENT sid="8" pm="."><plain>Factors influencing OS and DFS were cytoreductive score, primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, and disease-free interval of more than 12 months on univariate analysis </plain></SENT>
<SENT sid="9" pm="."><plain>The only factors that remained significant for prognosis after multivariate analysis were primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and cytoreductive score </plain></SENT>
<SENT sid="10" pm="."><plain>Thirty-day morbidity was 56 %, and there were no 30-day mortalities </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> and HIPEC can be safely carried out in Asian patients with <z:e sem="disease" ids="C1332128" disease_type="Neoplastic Process" abbrv="">peritoneal carcinomatosis</z:e> from ovarian, colorectal, appendiceal, <z:mpath ids='MPATH_365'>mesothelioma</z:mpath>, and primary peritoneal origins </plain></SENT>
<SENT sid="12" pm="."><plain>Overall, the ovarian, appendiceal, <z:mpath ids='MPATH_365'>mesothelioma</z:mpath>, and primary <z:e sem="disease" ids="C0153467" disease_type="Neoplastic Process" abbrv="">peritoneal cancer</z:e> patients tended to do better than the colorectal patients, but careful patient selection ensuring that optimal cytoreduction can be achieved is essential for the success of this procedure </plain></SENT>
</text></document>